09:37 AM EST, 11/21/2025 (MT Newswires) -- BioSyent ( BIOYF ) , a profitable growth-oriented specialty pharmaceutical company, was up more than 5% early Friday after it overnight Thursday said third quarter net income and net revenue both advanced as each of its three businesses "performed well" over the period, while the company noted its FeraMAX and Tibella/Tibelia products continue to generate profitable sales growth, both in Canada and internationally.

For Q3, net earnings jumped 16% to near $2.7 million, from just above $2.3 million. Fully Diluted EPS of $0.23 was up 19%

Total company sales rose 28% to more than $12.2 million over the same period.

Chief executive Rene Goehrum said: "Though we experienced some gross margin compression on changes in sales mix, our overall EBITDA margin in Q3 2025 remained consistent with the comparative period at 30% to sales as operating expenses were maintained in proportion to sales growth. On a year-to-date basis, total company sales increased by 27% with an EBITDA margin of 29% to sales.

"On a year-to-date basis, total company sales increased by 27% with an EBITDA margin of 29% to sales," he added.

Goehrum said in just over one year since the company's September 2024 acquisition of the worldwide rights to Tibella/Tibelia, this product has generated "incremental sales and profit growth" in line with its initial expectations. "As we enter the final weeks of the year, we remain focused on continued profitable growth and momentum in our businesses through the end of 2025 and into 2026."

BioSyent ( BIOYF ) will pay a regular quarterly cash dividend of $0.05, on Dec. 15.

Price: 11.52, Change: +0.80, Percent Change: +7.46